{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:21:58Z","timestamp":1790990518036,"version":"4.1.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T00:00:00Z","timestamp":1516233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T00:00:00Z","timestamp":1516233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Vaccine development against <jats:italic>Plasmodium vivax<\/jats:italic> malaria lags behind that for <jats:italic>Plasmodium falciparum<\/jats:italic>. To narrow this gap, we administered recombinant antigens based on <jats:italic>P. vivax<\/jats:italic> circumsporozoite protein (CSP) to mice. We expressed in <jats:italic>Pichia pastoris<\/jats:italic> two chimeric proteins by merging the three central repeat regions of different CSP alleles (VK210, VK247, and <jats:italic>P. vivax<\/jats:italic>-like). The first construct (yPvCSP-All<jats:sub>FL<\/jats:sub>) contained the fused repeat regions flanked by N- and C-terminal regions. The second construct (yPvCSP-All<jats:sub>CT<\/jats:sub>) contained the fused repeat regions and the C-terminal domain, plus RI region. Mice were vaccinated with three doses of yPvCSP in adjuvants Poly (I:C) or Montanide ISA720. We also used replication-defective adenovirus vectors expressing CSP of human serotype 5 (AdHu5) and chimpanzee serotype 68 (AdC68) for priming mice which were subsequently boosted twice with yPvCSP proteins in Poly (I:C) adjuvant. Regardless of the regime used, immunized mice generated high IgG titres specific to all CSP alleles. After challenge with <jats:italic>P. berghei<\/jats:italic> ANKA transgenic parasites expressing Pb\/PvVK210 or Pb\/PvVK247 sporozoites, significant time delays for parasitemia were observed in all vaccinated mice. These vaccine formulations should be clinically tried for their potential as protective universal vaccine against <jats:italic>P. vivax<\/jats:italic> malaria.<\/jats:p>","DOI":"10.1038\/s41598-017-19063-6","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T12:37:33Z","timestamp":1515760653000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Prime-boost vaccination with recombinant protein and adenovirus-vector expressing Plasmodium vivax circumsporozoite protein (CSP) partially protects mice against Pb\/Pv sporozoite challenge"],"prefix":"10.1038","volume":"8","author":[{"given":"Tarsila Mendes","family":"de Camargo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elis\u00e2ngela Oliveira","family":"de Freitas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alba Marina","family":"Gimenez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luciana Chagas","family":"Lima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"de Almeida Caramico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K\u00e1tia Sanches","family":"Fran\u00e7oso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oscar","family":"Bruna-Romero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Andolina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7951-0745","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Nosten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"R\u00e9nia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hildegund C. J.","family":"Ertl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth S.","family":"Nussenzweig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Nussenzweig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauricio M.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2648-1696","authenticated-orcid":false,"given":"Arturo","family":"Reyes-Sandoval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene S.","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,18]]},"reference":[{"key":"19063_CR1","unstructured":"WHO. World Malaria Report 2015. WHO Library ISBN 978 92 4 156515 8 (2016)."},{"key":"19063_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-13-481","volume":"13","author":"BA Rahimi","year":"2014","unstructured":"Rahimi, B. A. et al. Severe vivax malaria: a systematic review and meta-analysis of clinical studies since 1900. Malar J 13, 481 (2014).","journal-title":"Malar J"},{"key":"19063_CR3","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1093\/cid\/ciu954","volume":"60","author":"A Ouattara","year":"2015","unstructured":"Ouattara, A. & Laurens, M. B. Vaccines against malaria. Clin Infect Dis 60, 930\u2013936 (2015).","journal-title":"Clin Infect Dis"},{"key":"19063_CR4","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1586\/14760584.2.2.231","volume":"2","author":"N Garcon","year":"2003","unstructured":"Garcon, N., Heppner, D. G. & Cohen, J. Development of RTS,S\/AS02: a purified subunit-based malaria vaccine candidate formulated with a novel adjuvant. Expert Rev Vaccines 2, 231\u2013238 (2003).","journal-title":"Expert Rev Vaccines"},{"key":"19063_CR5","doi-asserted-by":"publisher","first-page":"e1001685","DOI":"10.1371\/journal.pmed.1001685","volume":"11","author":"SCTP Rts","year":"2014","unstructured":"Rts, S. C. T. P. Efficacy and safety of the RTS,S\/AS01 malaria vaccine during 18 months after vaccination: a phase 3 randomized, controlled trial in children and young infants at 11 African sites. PLoS Med 11, e1001685 (2014).","journal-title":"PLoS Med"},{"key":"19063_CR6","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1126\/science.2414847","volume":"230","author":"DE Arnot","year":"1985","unstructured":"Arnot, D. E. et al. Circumsporozoite protein of Plasmodium vivax: gene cloning and characterization of the immunodominant epitope. Science 230, 815\u2013818 (1985).","journal-title":"Science"},{"key":"19063_CR7","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1126\/science.2672336","volume":"245","author":"R Rosenberg","year":"1989","unstructured":"Rosenberg, R. et al. Circumsporozoite protein heterogeneity in the human malaria parasite Plasmodium vivax. Science 245, 973\u2013976 (1989).","journal-title":"Science"},{"key":"19063_CR8","doi-asserted-by":"crossref","first-page":"16297","DOI":"10.1016\/S0021-9258(18)55295-9","volume":"266","author":"SH Qari","year":"1991","unstructured":"Qari, S. H. et al. Wide distribution of the variant form of the human malaria parasite Plasmodium vivax. J Biol Chem 266, 16297\u201316300 (1991).","journal-title":"J Biol Chem"},{"key":"19063_CR9","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1016\/0140-6736(93)90559-Y","volume":"341","author":"SH Qari","year":"1993","unstructured":"Qari, S. H. et al. Identification of Plasmodium vivax-like human malaria parasite. Lancet 341, 780\u2013783 (1993).","journal-title":"Lancet"},{"key":"19063_CR10","doi-asserted-by":"publisher","first-page":"1485","DOI":"10.1093\/infdis\/168.6.1485","volume":"168","author":"SH Qari","year":"1993","unstructured":"Qari, S. H. et al. Global occurrence of Plasmodium vivax-like human malaria parasite. J Infect Dis 168, 1485\u20131489 (1993).","journal-title":"J Infect Dis"},{"key":"19063_CR11","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/S0035-9203(00)90110-X","volume":"94","author":"RL Machado","year":"2000","unstructured":"Machado, R. L. & Povoa, M. M. Distribution of Plasmodium vivax variants (VK210, VK247 and P. vivax-like) in three endemic areas of the Amazon region of Brazil and their correlation with chloroquine treatment. Trans R Soc Trop Med Hyg 94, 377\u2013381 (2000).","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"19063_CR12","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1590\/S0074-02762007005000041","volume":"102","author":"ME Arruda","year":"2007","unstructured":"Arruda, M. E., Zimmerman, R. H., Souza, R. M. & Oliveira-Ferreira, J. Prevalence and level of antibodies to the circumsporozoite protein of human malaria parasites in five states of the Amazon region of Brazil. Mem Inst Oswaldo Cruz 102, 367\u2013371 (2007).","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"19063_CR13","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1128\/IAI.01667-06","volume":"75","author":"A Yadava","year":"2007","unstructured":"Yadava, A. et al. A novel chimeric Plasmodium vivax circumsporozoite protein induces biologically functional antibodies that recognize both VK210 and VK247 sporozoites. Infect Immun 75, 1177\u20131185 (2007).","journal-title":"Infect Immun"},{"key":"19063_CR14","doi-asserted-by":"publisher","first-page":"e3268","DOI":"10.1371\/journal.pntd.0003268","volume":"8","author":"A Yadava","year":"2014","unstructured":"Yadava, A. et al. Protective efficacy of a Plasmodium vivax circumsporozoite protein-based vaccine in Aotus nancymaae is associated with antibodies to the repeat region. PLoS Negl Trop Dis 8, e3268 (2014).","journal-title":"PLoS Negl Trop Dis"},{"key":"19063_CR15","doi-asserted-by":"publisher","first-page":"e0004423","DOI":"10.1371\/journal.pntd.0004423","volume":"10","author":"JW Bennett","year":"2016","unstructured":"Bennett, J. W. et al. Phase 1\/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001\/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy. PLoS Negl Trop Dis 10, e0004423 (2016).","journal-title":"PLoS Negl Trop Dis"},{"key":"19063_CR16","doi-asserted-by":"publisher","first-page":"1347","DOI":"10.4049\/jimmunol.1100302","volume":"187","author":"A Reyes-Sandoval","year":"2011","unstructured":"Reyes-Sandoval, A. et al. CD8+ T effector memory cells protect against liver-stage malaria. J Immunol 187, 1347\u20131357 (2011).","journal-title":"J Immunol"},{"key":"19063_CR17","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3389\/fimmu.2012.00358","volume":"3","author":"JR Vasconcelos","year":"2012","unstructured":"Vasconcelos, J. R. et al. Relevance of long-lived CD8(+) T effector memory cells for protective immunity elicited by heterologous prime-boost vaccination. Front Immunol 3, 358 (2012).","journal-title":"Front Immunol"},{"key":"19063_CR18","doi-asserted-by":"publisher","first-page":"2181","DOI":"10.1016\/j.vaccine.2014.02.053","volume":"32","author":"AP Almeida","year":"2014","unstructured":"Almeida, A. P. et al. Long-lasting humoral and cellular immune responses elicited by immunization with recombinant chimeras of the Plasmodium vivax circumsporozoite protein. Vaccine 32, 2181\u20132187 (2014).","journal-title":"Vaccine"},{"key":"19063_CR19","doi-asserted-by":"publisher","first-page":"e55571","DOI":"10.1371\/journal.pone.0055571","volume":"8","author":"I Chuang","year":"2013","unstructured":"Chuang, I. et al. DNA prime\/Adenovirus boost malaria vaccine encoding P. falciparum CSP and AMA1 induces sterile protection associated with cell-mediated immunity. PLoS One 8, e55571 (2013).","journal-title":"PLoS One"},{"key":"19063_CR20","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1093\/infdis\/jiw244","volume":"214","author":"T Rampling","year":"2016","unstructured":"Rampling, T. et al. Safety and High Level Efficacy of the Combination Malaria Vaccine Regimen of RTS,S\/AS01B With Chimpanzee Adenovirus 63 and Modified Vaccinia Ankara Vectored Vaccines Expressing ME-TRAP. J Infect Dis 214, 772\u2013781 (2016).","journal-title":"J Infect Dis"},{"key":"19063_CR21","doi-asserted-by":"publisher","first-page":"e106241","DOI":"10.1371\/journal.pone.0106241","volume":"9","author":"M Sedegah","year":"2014","unstructured":"Sedegah, M. et al. Sterile immunity to malaria after DNA prime\/adenovirus boost immunization is associated with effector memory CD8+ T cells targeting AMA1 class I epitopes. PLoS One 9, e106241 (2014).","journal-title":"PLoS One"},{"key":"19063_CR22","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms3836","volume":"4","author":"KJ Ewer","year":"2013","unstructured":"Ewer, K. J. et al. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation. Nat Commun 4, 2836 (2013).","journal-title":"Nat Commun"},{"issue":"Suppl 1","key":"19063_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1590\/S0074-02762011000900021","volume":"106","author":"AG Camacho","year":"2011","unstructured":"Camacho, A. G. et al. TLR5-dependent immunogenicity of a recombinant fusion protein containing an immunodominant epitope of malarial circumsporozoite protein and the FliC flagellin of Salmonella Typhimurium. Mem Inst Oswaldo Cruz 106(Suppl 1), 167\u2013171 (2011).","journal-title":"Mem Inst Oswaldo Cruz"},{"key":"19063_CR24","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1128\/CVI.00312-13","volume":"20","author":"MT Leal","year":"2013","unstructured":"Leal, M. T. et al. Immunogenicity of recombinant proteins consisting of Plasmodium vivax circumsporozoite protein allelic variant-derived epitopes fused with Salmonella enterica Serovar Typhimurium flagellin. Clin Vaccine Immunol 20, 1418\u20131425 (2013).","journal-title":"Clin Vaccine Immunol"},{"key":"19063_CR25","doi-asserted-by":"publisher","first-page":"793","DOI":"10.1128\/IAI.01410-13","volume":"82","author":"LH Teixeira","year":"2014","unstructured":"Teixeira, L. H. et al. Immunogenicity of a prime-boost vaccine containing the circumsporozoite proteins of Plasmodium vivax in rodents. Infect Immun 82, 793\u2013807 (2014).","journal-title":"Infect Immun"},{"key":"19063_CR26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1084\/jem.156.1.20","volume":"156","author":"EH Nardin","year":"1982","unstructured":"Nardin, E. H. et al. Circumsporozoite proteins of human malaria parasites Plasmodium falciparum and Plasmodium vivax. J Exp Med 156, 20\u201330 (1982).","journal-title":"J Exp Med"},{"key":"19063_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/srep46482","volume":"7","author":"AM Salman","year":"2017","unstructured":"Salman, A. M. et al. Rational development of a protective P. vivax vaccine evaluated with transgenic rodent parasite challenge models. Sci Rep 7, 46482 (2017).","journal-title":"Sci Rep"},{"key":"19063_CR28","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1128\/IAI.01169-13","volume":"82","author":"EC Vicentin","year":"2014","unstructured":"Vicentin, E. C. et al. Invasion-inhibitory antibodies elicited by immunization with Plasmodium vivax apical membrane antigen-1 expressed in Pichia pastoris yeast. Infect Immun 82, 1296\u20131307 (2014).","journal-title":"Infect Immun"},{"key":"19063_CR29","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1186\/s13071-016-1862-1","volume":"9","author":"AM Gimenez","year":"2016","unstructured":"Gimenez, A. M. et al. A recombinant multi-antigen vaccine formulation containing Babesia bovis merozoite surface antigens MSA-2a1, MSA-2b and MSA-2c elicits invasion-inhibitory antibodies and IFN-gamma producing cells. Parasit Vectors 9, 577 (2016).","journal-title":"Parasit Vectors"},{"key":"19063_CR30","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.3389\/fimmu.2017.01275","volume":"8","author":"AM Gimenez","year":"2017","unstructured":"Gimenez, A. M. et al. Vaccine Containing the Three Allelic Variants of the Plasmodium vivax Circumsporozoite Antigen Induces Protection in Mice after Challenge with a Transgenic Rodent Malaria Parasite. Front Immunol 8, 1275 (2017).","journal-title":"Front Immunol"},{"key":"19063_CR31","doi-asserted-by":"publisher","first-page":"3","DOI":"10.4269\/ajtmh.2005.73.3","volume":"73","author":"S Herrera","year":"2005","unstructured":"Herrera, S. et al. Safety and elicitation of humoral and cellular responses in colombian malaria-naive volunteers by a Plasmodium vivax circumsporozoite protein-derived synthetic vaccine. Am J Trop Med Hyg 73, 3\u20139 (2005).","journal-title":"Am J Trop Med Hyg"},{"key":"19063_CR32","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1093\/infdis\/jiv154","volume":"212","author":"DA Espinosa","year":"2015","unstructured":"Espinosa, D. A. et al. Proteolytic Cleavage of the Plasmodium falciparum Circumsporozoite Protein Is a Target of Protective Antibodies. J Infect Dis 212, 1111\u20131119 (2015).","journal-title":"J Infect Dis"},{"key":"19063_CR33","doi-asserted-by":"publisher","first-page":"29","DOI":"10.3389\/fmicb.2015.00029","volume":"6","author":"KL Wilson","year":"2015","unstructured":"Wilson, K. L., Xiang, S. D. & Plebanski, M. Montanide, Poly I:C and nanoparticle based vaccines promote differential suppressor and effector cell expansion: a study of induction of CD8 T cells to a minimal Plasmodium berghei epitope. Front Microbiol 6, 29 (2015).","journal-title":"Front Microbiol"},{"key":"19063_CR34","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4269\/ajtmh.2011.10-0110","volume":"84","author":"M Arevalo-Herrera","year":"2011","unstructured":"Arevalo-Herrera, M. et al. Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants. Am J Trop Med Hyg 84, 21\u201327 (2011).","journal-title":"Am J Trop Med Hyg"},{"key":"19063_CR35","doi-asserted-by":"publisher","first-page":"7256","DOI":"10.1016\/j.vaccine.2010.08.098","volume":"28","author":"K Tewari","year":"2010","unstructured":"Tewari, K. et al. Poly(I:C) is an effective adjuvant for antibody and multi-functional CD4+ T cell responses to Plasmodium falciparum circumsporozoite protein (CSP) and alphaDEC-CSP in non human primates. Vaccine 28, 7256\u20137266 (2010).","journal-title":"Vaccine"},{"key":"19063_CR36","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1128\/IAI.01108-12","volume":"81","author":"K Kastenmuller","year":"2013","unstructured":"Kastenmuller, K. et al. Full-length Plasmodium falciparum circumsporozoite protein administered with long-chain poly(I.C) or the Toll-like receptor 4 agonist glucopyranosyl lipid adjuvant-stable emulsion elicits potent antibody and CD4+ T cell immunity and protection in mice. Infect Immun 81, 789\u2013800 (2013).","journal-title":"Infect Immun"},{"key":"19063_CR37","doi-asserted-by":"publisher","first-page":"e31472","DOI":"10.1371\/journal.pone.0031472","volume":"7","author":"JJ Moon","year":"2012","unstructured":"Moon, J. J. et al. Antigen-displaying lipid-enveloped PLGA nanoparticles as delivery agents for a Plasmodium vivax malaria vaccine. PLoS One 7, e31472 (2012).","journal-title":"PLoS One"},{"key":"19063_CR38","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/0022-1759(94)00331-P","volume":"181","author":"RK Gupta","year":"1995","unstructured":"Gupta, R. K. & Siber, G. R. Method for quantitation of IgG subclass antibodies in mouse serum by enzyme-linked immunosorbent assay. J Immunol Methods 181, 75\u201381 (1995).","journal-title":"J Immunol Methods"},{"key":"19063_CR39","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1038\/35099560","volume":"413","author":"L Alexopoulou","year":"2001","unstructured":"Alexopoulou, L., Holt, A. C., Medzhitov, R. & Flavell, R. A. Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. Nature 413, 732\u2013738 (2001).","journal-title":"Nature"},{"key":"19063_CR40","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.immuni.2010.10.002","volume":"33","author":"RL Coffman","year":"2010","unstructured":"Coffman, R. L., Sher, A. & Seder, R. A. Vaccine adjuvants: putting innate immunity to work. Immunity 33, 492\u2013503 (2010).","journal-title":"Immunity"},{"key":"19063_CR41","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1038\/mt.2009.130","volume":"17","author":"MO Lasaro","year":"2009","unstructured":"Lasaro, M. O. & Ertl, H. C. New insights on adenovirus as vaccine vectors. Mol Ther 17, 1333\u20131339 (2009).","journal-title":"Mol Ther"},{"key":"19063_CR42","doi-asserted-by":"publisher","first-page":"1373","DOI":"10.1038\/mi.2015.29","volume":"8","author":"M Jeyanathan","year":"2015","unstructured":"Jeyanathan, M. et al. Novel chimpanzee adenovirus-vectored respiratory mucosal tuberculosis vaccine: overcoming local anti-human adenovirus immunity for potent TB protection. Mucosal Immunol 8, 1373\u20131387 (2015).","journal-title":"Mucosal Immunol"},{"key":"19063_CR43","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1016\/j.pt.2016.12.011","volume":"33","author":"M White","year":"2017","unstructured":"White, M., Amino, R. & Mueller, I. Theoretical Implications of a Pre-Erythrocytic Plasmodium vivax Vaccine for Preventing Relapses. Trends Parasitol 33, 260\u2013263 (2017).","journal-title":"Trends Parasitol"},{"key":"19063_CR44","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1016\/j.bbagen.2008.03.016","volume":"1780","author":"MC Jimenez","year":"2008","unstructured":"Jimenez, M. C. et al. Biophysical characterization of the recombinant merozoite surface protein-3 of Plasmodium vivax. Biochim Biophys Acta 1780, 983\u2013988 (2008).","journal-title":"Biochim Biophys Acta"},{"key":"19063_CR45","doi-asserted-by":"publisher","first-page":"6132","DOI":"10.1016\/j.vaccine.2008.08.070","volume":"26","author":"DY Bargieri","year":"2008","unstructured":"Bargieri, D. Y. et al. New malaria vaccine candidates based on the Plasmodium vivax Merozoite Surface Protein-1 and the TLR-5 agonist Salmonella Typhimurium FliC flagellin. Vaccine 26, 6132\u20136142 (2008).","journal-title":"Vaccine"},{"key":"19063_CR46","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1038\/nprot.2010.134","volume":"5","author":"D Zhou","year":"2010","unstructured":"Zhou, D. et al. An efficient method of directly cloning chimpanzee adenovirus as a vaccine vector. Nat Protoc 5, 1775\u20131785 (2010).","journal-title":"Nat Protoc"},{"key":"19063_CR47","doi-asserted-by":"publisher","DOI":"10.1186\/s12936-015-0830-0","volume":"14","author":"C Andolina","year":"2015","unstructured":"Andolina, C. et al. The suitability of laboratory-bred Anopheles cracens for the production of Plasmodium vivax sporozoites. Malar J 14, 312 (2015).","journal-title":"Malar J"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-19063-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-19063-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-19063-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T01:08:38Z","timestamp":1671584918000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-017-19063-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,18]]},"references-count":47,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["19063"],"URL":"https:\/\/doi.org\/10.1038\/s41598-017-19063-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,18]]},"assertion":[{"value":"30 March 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"1118"}}